Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study

Breuer, Judith, Drysdale, Myriam, Walker, Jill, Han, Jennifer, Aylott, Alicia, Van Dyke, Melissa K., Birch, Helen J., McKie, Elizabeth, Jordan, William, Gemzoe, Kim, Gillespie, Iain A., Bethune, Claire, Williams, Charlotte A., Underwood, Jonathan ORCID: https://orcid.org/0000-0001-6963-2821, Goodman, Anna L., Brown, Michael, Brown, Julianne R, Williams, Rachel, Bernal, Luz Marina Martin, Buggiotti, Laura, Gkrania-Klotsas, Effrossyni, Green, Clara, Hunter, Ewan, Miller, Charles, Skingsley, Andrew and Lowe, David M. 2025. Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study. Journal of Infection , 106510. 10.1016/j.jinf.2025.106510

[thumbnail of Monitoring the Emergence.pdf]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Objectives: To assess outcomes in sotrovimab-treated immunocompromised patients in the United Kingdom. Methods: Multicenter, prospective, observational, descriptive study in immunocompromised, non-hospitalized adults infected with SARS-CoV-2 who received intravenous sotrovimab 500 mg as standard-of-care (July 1, 2022–June 30, 2023; Omicron predominance). Virology analyses included determination of SARS-CoV-2 viral load, spike sequencing, and determination of amino-acid substitutions in the spike protein and sotrovimab epitope. Results: The proportion of participants (N=217) with undetectable SARS-CoV-2 RNA was 25.1% at day 7, 65.8% at day 14, and 83.5% at day 28. Of 156 participants with paired sequences, 101 (64.7%) and 47 (30.1%) had treatment-emergent substitutions at >50% allelic frequency in the spike protein and sotrovimab epitope, respectively, at any post-baseline timepoint. Ten treatment-emergent substitutions (at positions 337, 340, and 356) were identified in the epitope at >50% allelic frequency. Five of 18 (27.8%) participants with, versus 22/30 (73.3%) of those without, treatment-emergent epitope substitutions at day 14 achieved undetectable SARS-CoV-2 RNA levels at day 28. Conclusions: In this immunocompromised population infected with SARS-CoV-2 who received early treatment with sotrovimab, most participants (83.5%) experienced substantial viral load reductions by day 28. Treatment-emergent substitutions occurred in the sotrovimab epitope, including substitutions known to reduce susceptibility in vitro. Several treatment-emergent substitutions were associated with viral persistence.

Item Type: Article
Date Type: Published Online
Status: In Press
Schools: Schools > Medicine
Publisher: Elsevier
ISSN: 0163-4453
Funders: GSK
Date of First Compliant Deposit: 20 May 2025
Date of Acceptance: 11 May 2025
Last Modified: 21 May 2025 08:48
URI: https://orca.cardiff.ac.uk/id/eprint/178386

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics